Imagine being able to see something out of the corner of your eye, but struggling to make out the face directly in front of you. Or being young enough that driving, reading, and recognizing people should be effortless, while the vision needed to do those things is gradually disappearing.
That’s the reality for people with Stargardt disease, an inherited eye disorder that often begins in childhood or young adulthood and progressively damages central vision. It affects the macula, the small but critically important area at the center of the retina that allows us to see fine detail. As the disease advances, everyday tasks such as reading, recognizing faces, and driving can become increasingly difficult.
In most cases, Stargardt disease is caused by mutations in the ABCA4 gene. Normally, this gene helps produce a protein involved in clearing substances generated by the eye’s light-sensing cells. When that process breaks down, harmful byproducts related to vitamin A can accumulate in the retina, gradually damaging the cells needed for central vision.
Until now, that underlying process has been extraordinarily difficult to stop. But researchers are investigating a different approach: rather than trying to repair vision after those retinal cells have been lost, what if they could slow the buildup that damages them in the first place?
How Gildeuretinol Works
Alkeus Pharmaceuticals developed gildeuretinol by modifying vitamin A at the molecular level using deuterium, a naturally occurring, non-radioactive form of hydrogen. Rather than blocking vitamin A from reaching the eye entirely – which would impair night vision – the modification targets the specific chemical bond that causes dimerization, leaving the rest of the visual cycle intact.
Many visual cycle modulators – drugs that try to slow Stargardt disease by suppressing vitamin A metabolism broadly – carry side effects including night blindness and delayed dark adaptation. Gildeuretinol is designed to reduce vitamin A dimerization without modulating the visual cycle, avoiding that tradeoff. The drug is taken as a once-daily oral pill and gradually replaces the body’s natural vitamin A supply with the modified, dimer-resistant form.
What the TEASE-1 Trial Found
The study was led by Christine N. Kay, MD, of Vitreoretinal Associates in Gainesville, Florida. The randomized, double-masked, placebo-controlled TEASE-1 trial enrolled 50 patients aged 12 years or older with genetic Stargardt disease, across seven US clinics between 2015 and 2019. Participants were split into four groups: one received 14 mg gildeuretinol once daily for two years; another received 24 mg for year one before switching to 14 mg for year two; a third received placebo for two years; and a crossover group received placebo for year one then switched to the drug for year two.
The primary efficacy endpoint was the growth rate of retinal atrophic lesions over 24 months, tracked using specialized eye-imaging scans. To strengthen the comparison group – a common challenge in rare-disease research – researchers added observational data from 54 additional Stargardt patients tracked over time but not enrolled in the intervention.
Retinal lesions grew at a rate of 0.182 mm/year in patients taking gildeuretinol, compared with 0.232 mm/year in the untreated group, representing a 21.6% relative reduction in lesion growth rate (P < .001). When the analysis was restricted to actual trial participants only – excluding the supplemental observational data – lesion growth was still slower with the drug (0.206 mm/year) than with placebo (0.242 mm/year), a 14.9% relative reduction.
At six months, more than 80% of plasma vitamin A had been replaced with gildeuretinol in 39 of 40 treated participants, and this replacement was sustained throughout the treatment period. No patient-reported events of dark adaptation delays or night blindness occurred. Most side effects were mild to moderate and occurred at similar rates across all four groups.
The trial’s small sample size remains an important limitation. The full 21.6% lesion-reduction figure depends partly on the supplemental observational data added to the comparison group. Because vision loss in Stargardt disease progresses slowly and unevenly, visual acuity could not serve as a reliable primary endpoint.
FDA Designations and the Phase 3 Pipeline
Gildeuretinol has received Breakthrough Therapy, Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA for Stargardt disease. The FDA’s Breakthrough Therapy designation is granted when preliminary clinical evidence suggests a drug may offer substantial improvement over existing therapies for serious conditions. The European Medicines Agency has designated gildeuretinol as an orphan medicinal product to treat non-syndromic inherited retinal dystrophies due to ABCA4 gene defects, which includes Stargardt disease.
On September 4, 2026, Tarsus Pharmaceuticals (Nasdaq: TARS) completed its acquisition of Alkeus Pharmaceuticals, adding worldwide rights to gildeuretinol, according to a Tarsus press release. The ongoing phase 3 NORTHSTAR trial, registered on ClinicalTrials.gov, will assess the safety, efficacy, and pharmacokinetics of gildeuretinol in people with advanced Stargardt disease. It aims to enroll approximately 230 participants ages 8 to 45, with topline data expected in the second half of 2029.
Beyond Stargardt, gildeuretinol is also under investigation for geographic atrophy secondary to age-related macular degeneration, raising the possibility that the drug’s potential reach extends beyond a rare pediatric disease.
What This Means for Patients and Families
Gildeuretinol remains investigational and is not FDA-approved. The TEASE-1 data provide the strongest clinical evidence yet that slowing Stargardt disease with an oral drug is biologically possible, and that this mechanism achieves it without the night vision penalties associated with earlier visual cycle modulators.
The NORTHSTAR trial will enroll approximately 230 patients, randomized 1:1 to receive either placebo or gildeuretinol once daily for two years. Patients aged 8 to 45 with a Stargardt diagnosis may wish to ask a retinal specialist about enrollment eligibility. Topline results are expected in the second half of 2029, with a potential regulatory submission timeline emerging within the following years if data are positive.
Until now, Stargardt disease had no controlled trial evidence supporting any intervention. Families who have lived with a diagnosis and no options now have a phase 3 trial actively enrolling and peer-reviewed evidence published in JAMA Ophthalmology showing the underlying biology can be interrupted. If NORTHSTAR confirms what TEASE-1 suggested, gildeuretinol would represent the first approved therapy ever offered to people with Stargardt disease.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Natural Ways to Support Eye and Vision Health